Product Description
SST-6007, developed with SSTs proprietary KNOSISTM technology, is a patented topical cream product containing 5% sildenafil citrate by weight.
Mechanisms of Action: PDE5 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Strategic Science & Technologies
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Sexual Dysfunction, Physiological
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
SST-6007-02-01 | P2 |
Completed |
Sexual Dysfunction, Physiological |
2017-05-01 |